Duvelisib (IPI-145)

For research use only. Not for use in humans.

目录号:S7028 别名: INK1197 中文名称:杜韦利西布

Duvelisib (IPI-145) Chemical Structure

CAS No. 1201438-56-3

Duvelisib (IPI-145, INK1197) 是一种新型选择性PI3K δ/γ抑制剂,在无细胞试验中KiIC50分别为 23 pM/243 pM 和 1 nM/50 nM,对 PI3K δ/γ 的选择性比对其它蛋白激酶高。Phase 3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1557.22 现货
RMB 1409.65 现货
RMB 7967.14 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Duvelisib (IPI-145)发表文献33篇:

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Duvelisib (IPI-145, INK1197) 是一种新型选择性PI3K δ/γ抑制剂,在无细胞试验中KiIC50分别为 23 pM/243 pM 和 1 nM/50 nM,对 PI3K δ/γ 的选择性比对其它蛋白激酶高。Phase 3。
靶点
PI3Kδ [1]
(Cell-free assay)
PI3Kβ [1]
(Cell-free assay)
PI3Kγ [1]
(Cell-free assay)
23 pM(Ki) 1564 pM(Ki) 243 pM(Ki)
体外研究

IPI-145抑制鼠/人类 B细胞增殖,EC50 为0.5 nM/0.5 nM,也抑制人类T细胞增殖,EC50为9.5 nM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jurkat NWr6W49XWHKxbHnm[ZJifGmxbjDhd5NigQ>? MY[zJIRigXN? NGnI[49CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFr1dotifCClZXzsd{Bi\nSncjCzJIRigXNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3ME2xMlkh|pyv MorrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5N{SxNlcoRjJ5N{e0NVI4RC:jPh?=
MOLT4 M1Pve3Bzd2yrZnXyZZRqd25iYYPzZZk> NXruN2g1OyCmYYnz MoPXRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPT1zUOEBk\WyuczDh[pRmeiB|IHThfZMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OD1{LkOg{txO NWHEcpNHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O|QyOjdpPkK3O|c1OTJ5PD;hQi=>
MV4-11 MUjQdo9tcW[ncnH0bY9vKGG|c3H5 M4PaelMh\GG7cx?= NXjWU5BjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNWlQuOTFiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEmFNUC9OE41KM7:TR?= NVzIVVNqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O|QyOjdpPkK3O|c1OTJ5PD;hQi=>
MOLM14 MWXQdo9tcW[ncnH0bY9vKGG|c3H5 Mn;WN{Bl[Xm| NXHhdXRpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xOOTRiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEmFNUC9NU4zKM7:TR?= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd5NEGyO{c,Ojd5N{SxNlc9N2F-
Loucy MmnrVJJwdGmoZYLheIlwdiCjc4PhfS=> NEPMdmE{KGSjeYO= Mlf3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCOb4XjfUBk\WyuczDh[pRmeiB|IHThfZMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OD1yLkm4JO69VQ>? M4\jdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVI4Lz5{N{e3OFEzPzxxYU6=
JURKAT NX\0O4JNTnWwY4Tpc44h[XO|YYm= Ml;RNE4yNCBzLkCsJIFv\CB7LkCg{txO MVXJVGkyPDVid3HzJIFjdGVidH:gbY5pcWKrdDDBb5Qh[W6mIGO2JJBpd3OyaH;yfYxifGmxbjDhcoQhdW:mZYP0cJkh[W[oZXP0[YQh\3Kxd4ToJIlvKEqXUlvBWC=> M4fwbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUewNlY{Lz5|MEm3NFI3OzxxYU6=
MOLT3 MUDGeY5kfGmxbjDhd5NigQ>? MnftNE4yNCBzLkCsJIFv\CB7LkCg{txO NVTKNYJRUVCLMUS1JJdieyCjYnzlJJRwKGmwaHnibZQhSWu2IHHu[EBUPiCyaH;zdIhwenmuYYTpc44h[nW2IHLhdoVtgSCjZn\lZ5Rm\CC2aHWg[5Jwf3SqIH;mJG1QVFR|IGStRWxN M3jhXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUewNlY{Lz5|MEm3NFI3OzxxYU6=
Raji32 MWjGeY5kfGmxbjDhd5NigQ>? NHrnS5QyKM7:TR?= MYXl[oZm[3SrdnXsfUBqdXCjaYLl[EB1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHreC=> MmfWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB3OESyOVQoRjNyNUi0NlU1RC:jPh?=
Ramos460 MXfGeY5kfGmxbjDhd5NigQ>? MWWxJO69VQ>? M3nZb4Vn\mWldHn2[Yx6KGmvcHHpdoVlKHSqZTDwbI9{eGixconsZZRqd25ib3[gRYt1 M{XuRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNUi0NlU1Lz5|MEW4OFI2PDxxYU6=
HBL-1 NFLQXo1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXvVXXdmT0l3ME21MlMh|ryP M1nqUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyME[3O|cyLz5|MEC2O|c4OTxxYU6=
OCI-Ly3 M3nCNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGjIS|FIUTVyPUOuO{DPxE1? MmnQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNke3O|EoRjNyME[3O|cyRC:jPh?=
TMD-8 NHLDVIRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NU\kcY9JT0l3ME2wMlAxODVizszN MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB4N{e3NUc,OzByNke3O|E9N2F-
U-2932 NEfvc2FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlLQS2k2OD1zLkig{txO Ml7mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNke3O|EoRjNyME[3O|cyRC:jPh?=
Farage NHnDfHdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV7HTVUxRTBwMESg{txO NVzwepRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOlc4PzFpPkOwNFY4PzdzPD;hQi=>
SU-DHL-10 MnK2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{HxWmdKPTB;Mj60JO69VQ>? NYGxS4tORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOlc4PzFpPkOwNFY4PzdzPD;hQi=>
SU-DHL-4 M1WxXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1fjU2dKPTB;MD6yJO69VQ>? M2PaT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyME[3O|cyLz5|MEC2O|c4OTxxYU6=
Karpas-422 NIS0SYhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3TGVmdKPTB;MD6xJO69VQ>? NWXqd3FGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOlc4PzFpPkOwNFY4PzdzPD;hQi=>
DOHH-2 M1LueWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUPHTVUxRTBwMEWg{txO MlLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNke3O|EoRjNyME[3O|cyRC:jPh?=
WSU-NHL MmGyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2GxUGdKPTB;MD6wNFgh|ryP NEDLb4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC2O|c4OSd-M{CwOlc4PzF:L3G+
Jeko-1 M1\rUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHrsbmNIUTVyPUGuN{DPxE1? NXPXNFU4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOlc4PzFpPkOwNFY4PzdzPD;hQi=>
Mino MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MontS2k2OD1|LkSg{txO MnL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNke3O|EoRjNyME[3O|cyRC:jPh?=
NCI-H929 MlXBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFvWRppIUTVyPUGg{txO MnfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNke3O|EoRjNyME[3O|cyRC:jPh?=
HH M4LmRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWfHTVUxRTBwMEGg{txO MnrXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNke3O|EoRjNyME[3O|cyRC:jPh?=
BJAB NF;4bllE\WyuII\pZYJqdGm2eTDhd5NigQ>? NFzkc20xNjFuIEGsJFUh|ryP MnL0OFgh[W6mIEeyJIg> M{f6S4lvcGmkaYTl[EBk\WyuIHfyc5d1cA>? MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV{MkK3PEc,Ojl3MkKyO|g9N2F-
LCL M2PhVWNmdGxidnnhZoltcXS7IHHzd4F6 NYLEZZM6OC5zLDCxMEA2KM7:TR?= Mn3SOFgh[W6mIEeyJIg> NH;JVFJqdmirYnn0[YQh[2WubDDndo94fGh? NFqwV3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWyNlI4QCd-Mkm1NlIzPzh:L3G+
insect cells NFXERlhHfW6ldHnvckBie3OjeR?= MVW1JI1qdnN? MnzPTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCFLYTldo1qdmGuIFjpd|YufGGpZ3XkJJAyOTCpYX3tZUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJJV{cW6pIIDoc5NxcGG2aXT5cIlvd3OrdH;sJIF{KHO3YoP0doF1\SCrbjDwdoV{\W6lZTDv[kBo[W2vYT2zNnAuSVSSIHHmeIVzKDVibXnud{BjgSC2aHnuJIxigWW{IHPodo9u[XSxZ4LhdIhq[yCvZYToc4QtKEmFNUCgQUAxNjFizszNMi=> M1rNeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMxOzl3MEKvK|5EcEWPQly8M4E,
Sf21 NFzNRVlHfW6ldHnvckBie3OjeR?= NFHyXG02KG2rboO= MVfJcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiSHnzOk11[WepZXSgdoVkd22kaX7hcpQh\nWubD3s[Y5ofGhiaIXtZY4heDFzMHTlcJRiN3WwdHHn[4VlKHKnY3;tZolv[W62IH\1cIwhdGWwZ4ToJJA5PWGucHjhJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDT[lIyKGOnbHzzJJV{cW6pIIDoc5NxcGG2aXT5cIlvd3OrdH;sJIF{KHO3YoP0doF1\SCrbjDwdoV{\W6lZTDv[kBo[W2vYT2zNnAuSVSSIHHmeIVzKDVibXnud{BjgSC2aHnuJIwtKEmFNUCgQUAxNjFizszNMi=> M3\JNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMxOzl3MEKvK|5EcEWPQly8M4E,
splenic B NWXzXpBkSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MUmzNEBucW6| NFXvfW9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGJidGJxYzDtc5V{\SC|cHzlcolkKEJiY3XscJMheHKnaX7jeYJifGWmIH\vdkA{OCCvaX7zJIZwdGyxd3XkJIJ6KEySUzDvdkBHMGGkJzmyJIRwdmuneTDhcpRqNW2xdYPlJGloVSCjbnSgdoVkd22kaX7hcpQhdW:3c3WgTWw1KHO2aX31cIF1cW:wIH3lZZN2emWmIHHmeIVzKDd{IHjyd{BjgSCDbHHtZZIhSmy3ZTDy[YR2[3Srb36gZZN{[XluIFXDOVAhRSByLkGg{txONg>? NY\CZ4FKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzB|OUWwNk8oRkOqRV3CUFww[T5?
Sf21 NGHQR5lHfW6ldHnvckBie3OjeR?= M{PRblUhdWmwcx?= NHX0UINKdmirYnn0bY9vKG:oIF6teIVzdWmwYXygTIl{Pi22YXfn[YQhemWlb33ibY5idnRiZoXscE1t\W6pdHigbJVu[W5icEGxNIJmfGFxdX70ZYdo\WRicnXjc41jcW6jboSg[pVtdCCuZX7neIgheDh3YXzwbIEh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJHNnOjFiY3XscJMhfXOrbnegdIhwe3CqYYTp[JltcW6xc3n0c4wh[XNic4Xid5Rz[XSnIHnuJJBz\XOnbnPlJI9nKGejbX3hMVMzWC2DVGCgZYZ1\XJiNTDtbY5{KGK7IITobY4hdGFuIFnDOVAhRSBzIN88UU4> NWT4NmJERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzB|OUWwNk8oRkOqRV3CUFww[T5?
Sf21 NVHEe2MzTnWwY4Tpc44h[XO|YYm= NEPHNHQ2KG2rboO= Mme5TY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFjpd|YufGGpZ3XkJJJm[2:vYnnuZY51KG[3bHytcIVv\3SqIHj1cYFvKHBzMUDhcJBp[S:3boTh[4dm\CC{ZXPvcYJqdmGwdDDmeYxtKGynbnf0bEBpfW2jbjDwPFVidHCqYTDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[yNUBk\WyuczD1d4lv\yCyaH;zdIhifGmmeXzpco9{cXSxbDDhd{B{fWK|dILheIUhcW5icILld4Vv[2Vib3[g[4FudWFvM{LQMWFVWCCjZoTldkA2KG2rboOgZpkhNCCLQ{WwJF0hOTBizszNMi=> NV\DOmw{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzB|OUWwNk8oRkOqRV3CUFww[T5?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-MAPK / MAPK ; 

PubMed: 27174919     


AML cell lines and primary AML blasts were treated with increasing doses of IPI-145 (nM) and cultured for 4 hours. Whole cell extracts were prepared and Western blot analysis was conducted for pAKT, pMAPK, and total AKT and MAPK protein levels.

PI3Kγ / PI3Kδ ; 

PubMed: 29522278     


Effects of duvelisib on the PI3K/Akt pathway in B and T cell lines. EBV-negative B cell lines [BJAB and Akata (-)], EBV-positive B cell lines [Akata (+), Mutu I, LCL, Raji, and P3HR1], and EBV-negative T cell line (Jurkat) were treated without (-) or with 1 or 5 μmol/L duvelisib for 48 h. Cell lysates were then immunoblotted for the indicated proteins involved in PI3K/Akt signaling.

27174919 29522278
体内研究 IPI-145 按10 mg/kg剂量口服处理给药小鼠和大鼠,具有良好的药代动力学, Cmax 和AUC分别为390 ng/mL 和 137 ng•h/mL。IPI-145 (10 mg/kg) 有效作用于鼠DTH 模型,约~50% 耳肿胀。IPI-145 (10 mg/kg) 有效作用于大鼠胶原诱导的关节炎(CIA)模型,这种作用具有剂量依赖性。IPI-145 作用于大鼠CIA模型,防止发炎,且保护关节骨和软骨。IPI-145 (10 mg/kg,QD)有效作用于大鼠佐剂性多关节炎模型。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 83 mg/mL (199.1 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 416.86
化学式

C22H17ClN6O

CAS号 1201438-56-3
储存条件 粉状
溶于溶剂
别名 INK1197

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02307461 Completed Drug: IPI-145 (duvelisib)|Drug: IPI-145 Healthy SecuraBio November 2014 Phase 1
NCT02095587 Completed Drug: IPI-145 Hepatic Impairment SecuraBio March 2014 Phase 1
NCT01947777 Completed Drug: IPI-145|Drug: Rifampin Healthy SecuraBio October 2013 Phase 1
NCT01925911 Completed Drug: IPI-145|Drug: Midazolam Healthy SecuraBio August 2013 Phase 1
NCT01836861 Completed Drug: IPI-145 Healthy SecuraBio March 2013 Phase 1
NCT01549106 Completed Drug: IPI-145|Drug: Placebo Healthy Volunteers SecuraBio August 2011 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Whether IPI-145 S7028 is mixture of two chiral forms, if not, which form is it?

  • 回答:

    S7028 IPI-145 is S form.

免费分装抑制剂

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买Duvelisib (IPI-145) | Duvelisib (IPI-145)供应商 | 采购Duvelisib (IPI-145) | Duvelisib (IPI-145)价格 | Duvelisib (IPI-145)生产 | 订购Duvelisib (IPI-145) | Duvelisib (IPI-145)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID